Galera Therapeutics (OTCQB: GRTX) is a biopharmaceutical company that historically developed small molecule superoxide dismutase (SOD) mimetics to reduce side effects of radiotherapy in cancer patients. Its lead programs, avasopasem and rucosopasem, targeted severe oral mucositis (SOM), one of the most common complications of radiotherapy. In October 2025, the company sold its assets related to avasopasem and rucosopasem, leaving the company without its core drug portfolio as of the 10-K filing date of March 19, 2026. The company trades on the OTCQB Market. J. Mel Sorensen, M.D. serves as President and Chief Executive Officer. The balance sheet carries a royalty purchase liability and warrant liability, reflecting prior financing arrangements with Clarus IV Galera Royalty AIV, L.P. and a subsequent assignment to Blackstone as of October 2025. As of the fiscal year ended December 31, 2025, the company reported an accumulated deficit and no disclosed product revenue.

Revenue model

As of the fiscal year ended December 31, 2025, the company had no disclosed product revenue. Prior financing was structured as a royalty purchase agreement with Clarus IV Galera Royalty AIV, L.P., later assigned to Blackstone in October 2025. The company has relied on equity offerings, including securities purchase agreements dated February 2023 and December 2024, to fund operations.

Products and services

Avasopasem and rucosopasem, both SOD mimetics targeting severe oral mucositis in radiotherapy patients. Both programs were sold in October 2025. No replacement pipeline is disclosed in the 10-K filed March 19, 2026.

Customers and end markets

Target end market was oncology, specifically cancer patients undergoing radiotherapy and the healthcare providers treating them. No commercial product sales to customers are disclosed in the filing.

Value-chain role

Clinical-stage drug developer relying on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) for manufacturing and trial execution. Patheon Manufacturing Services LLC served as a manufacturing partner under a Master Manufacturing Services Agreement dated August 13, 2021.

Geographic exposure

Incorporated and headquartered in the United States. Clinical trials conducted in the U.S. and abroad per the 10-K filed March 19, 2026. No specific international revenue or geographic revenue breakdown is disclosed.

Source: SEC 10-K, filed 2026-03-19

Industry: Pharmaceutical Preparations Peers: Applied Therapeutics, Inc. Dyadic International Inc Cidara Therapeutics, Inc. Quince Therapeutics Inc Scorpius Holdings, Inc. IN8bio Inc Mustang Bio Inc TAO Synergies Inc Rubius Therapeutics, Inc.